Access to Genetic Counselor Services Act of 2025
Summary
HR 6280, the Access to Genetic Counselor Services Act of 2025, is an early-stage bill that would expand Medicare Part B coverage to include genetic counseling services starting January 1, 2027. The bill has no direct funding authorization and is in the earliest legislative stages, with zero near-term market impact. Medicare Advantage insurers face a negligible incremental cost, but the bill's primary beneficiaries are genetic counselors, not publicly traded companies.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR 6280 is an early-stage bill with no committee action in six months; passage probability is low.
- 2.The bill authorizes no funding; it only expands Medicare Part B coverage to include genetic counseling services.
- 3.No publicly traded company is a direct beneficiary; Medicare Advantage insurers face negligible incremental costs.
- 4.The effective date of January 1, 2027 means any impact is at least 7 months away even if the bill were to pass.
Market Implications
The bill has no near-term market implications. It is stuck in committee with no momentum. Even if passed, the coverage expansion is small relative to the $1 trillion+ Medicare program. Investors should ignore this bill until it shows signs of legislative progress, such as a committee markup or CBO score.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Same as above: Medicare Part B coverage expansion for genetic counseling services.
Who must act
CMS and MACs must implement billing for genetic counselors under Part B.
What happens
Humana's Medicare Advantage plans must cover genetic counseling services for its ~5 million Medicare Advantage members, adding a small incremental medical cost.
Stock impact
Humana's Medicare Advantage business is its primary revenue driver (~$100B annual revenue). The added cost of genetic counseling coverage is negligible relative to total medical costs, and any benefit from early detection is uncertain. Net impact is neutral.
What the bill does
Same as above: Medicare Part B coverage expansion for genetic counseling services.
Who must act
CMS and MACs must implement billing for genetic counselors under Part B.
What happens
Cigna's Medicare Advantage plans (through Cigna-HealthSpring) must cover genetic counseling services for its ~1 million Medicare Advantage members, adding a small incremental medical cost.
Stock impact
Cigna's Medicare Advantage business is a smaller portion of its ~$200B annual revenue. The added cost is negligible. Net impact is neutral.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Great American Healthcare Plan
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.